Skip to main content
OpenTrials
Completed

NCT Number: NCT06159842

Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

The goal of this clinical trial is to test how safe and effective it is to treat early form of cancer cells found in the upper skin layer of the face, using a light-sensitive cream used in combination with a light source.

The main questions this trial aims to answer are:

* to confirm using laboratory testing, how much of the affected facial skin cancer section the treatment was able to remove, and; * seeing how many participants had no remaining affected facial skin cancer sections after treatment.

Participants who qualify will be asked to complete 12 visits in total and will receive a total of two treatments, after voluntarily consent has been given.

Completed

Looking for future studies?

Notify Me

Key information

About this study

In the study, participants will be asked to complete the following:

  • Provide basic personal information (including date of birth, gender, race and ethnicity)
  • Provide their medical/ surgical history and perform a medical exam (including but not limited to physical exam, skin type, vital signs, height, weight and urine pregnancy test collection)
  • Follow study rules such as avoiding certain medications and treatments
  • Allow photographs of the area of skin cancer being treated on the face
  • Provide information on any medications, treatments or reactions that started after the study began
  • Allow two treatments on the skin cancer area of the face using a light-sensitive cream used in combination with a light source
  • Allow clinical documentation of the treatment, such as how well the treatment was tolerated, any skin reaction or side effects
  • Allow surgery to remove the skin cancer area from the face for Laboratory testing

To qualify for this trial, participants must:

  • be an adult (18 years of age or older)
  • give voluntary written consent
  • have a recently diagnosed (less than six months from first visit) skin cancer area on the face that meets surgery size requirements
  • be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas
  • (if female) not be pregnant before and during the study and agree to use acceptable forms of birth control
  • confirm they are not sensitive to any of the study treatment ingredients

All surgery samples collected from the participants towards the end of the study will be sent to a laboratory for testing. All photographs of the treatment area collected during the study will be used as study data.

All participants have the right to refuse further participation in the study at any time.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Must be an adult (18 years of age or older)
  • Voluntary written consent required
  • Must have a recently diagnosed (no more than six months from first study visit) facial isSCC lesion that meets surgery excision size requirements
  • Cannot have other dermatological disease in the isSCC target area
  • Must be willing to follow study instructions and complete study requirements, including not using non-approved lotions and creams on the treatments areas
  • If female, cannot be pregnant before and during the study and agree to use acceptable forms of birth control

Exclusion criteria

  • Sensitive to any of the study treatment ingredients
  • Pregnant or lactating
  • Medical laboratory evidence of other non-isSCC tumor in the target lesion biopsy specimen
  • History of recurrence in the target isSCC lesion
  • Medical laboratory evidence of certain growth patterns in the target lesion biopsy specimen
  • Chronic medical condition that in the Investigators opinion will interfere in the trial or affect participant safety

Treatment and study plan

Aminolevulinic Acid 20% Topical Solution with Blue Light

Combination Product

Participants will have their facial isSCC prepped then treated with Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA), followed by blue light therapy administered for 16 minutes and 40 seconds to deliver the total desired light dose to the isSCC lesion.

Other names: Levulan® Kerastick®, BLU-U® Blue Light Photodynamic Therapy Illuminator

Primary outcomes

  1. Number of participants with Histological Clearance of treated isSCC lesion

    Time frame: Up to 16 weeks

    Histological clearance is defined as the absence of detectable evidence of isSCC tumor cell nests by the central pathology reports

Secondary outcomes

  1. Number of participants with clinical clearance of treated isSCC lesion

    Time frame: through treatment completion, an average of 12 weeks

    Complete Clinical Clearance will be measured by the Investigator and is defined as when there is no clinically visible lesion remaining at the site.

  2. Local Skin Response Scale

    Time frame: up to 16 weeks

    Observations and changes noted in the aesthetic appearance (Erythema, Flaking/ Scaling, Crusting, Swelling, Vesiculation/ Pustulation, Erosion/ Ulceration) of the treated isSCC lesion will each be graded on a scale of 0 to 4, with 0 as no presence and 4 as a severe outcome.

Sponsors and collaborators

Lead sponsor

The Center for Clinical and Cosmetic Research

Other

Collaborators

  • Sun Pharmaceutical Industries Limited

Registry information

Official study title

An Investigator Initiated Study to Evaluate the Safety and Efficacy of Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick®) (ALA) + Blue Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 7, 2023
Registry last updated
Feb 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.